Disappointing outcome of bitopertin treatment for negative symptoms in schizophrenia

June 14, 2017, Elsevier
Functional magnetic resonance imaging (fMRI) and other brain imaging technologies allow for the study of differences in brain activity in people diagnosed with schizophrenia. The image shows two levels of the brain, with areas that were more active in healthy controls than in schizophrenia patients shown in orange, during an fMRI study of working memory. Credit: Kim J, Matthews NL, Park S./PLoS One.

Two new phase III clinical trials investigating the efficacy and safety of bitopertin, a glycine uptake inhibitor considered to be a promising new add-on therapy for treating negative symptoms in schizophrenia, failed to show a benefit of the drug over placebo. The findings throw a wrench in the hopeful efforts to find a treatment for negative symptoms of schizophrenia, which account for some of the most debilitating aspects of the disorder and are associated with poorer outcomes in patients.

The outcomes of the trials were published in a paper in Biological Psychiatry by Dr. Dragana Bugarski-Kirola of Roche Pharmaceuticals in Basal, Switzerland. The randomized, double-blind, parallel-group, placebo-controlled studies were a collaboration between Roche and several research institutions around the world.

"We are back to the drawing board," said Dr. John Krystal, Editor of Biological Psychiatry.

Previous attempts to treat negative symptoms have employed drugs, hormones, and brain stimulation, but none have provided the desired clinical benefit. Research fingering glutamate signaling in negative symptoms has spurred the idea of targeting glutamate receptors, but this approach has failed in large trials. Glycine reuptake inhibitors have been considered a promising alterative to enhance glutamatergic signaling, and a small proof-of-concept study showed that bitopertin, which selectively inhibits glycine transporter type 1 (GlyT-1), reduced negative symptoms in stable patients with .

"GlyT-1 inhibition was one of the most promising approaches to the treatment of schizophrenia," said Krystal. "While it still may be possible to optimize GlyT-1 inhibition as a treatment, these negative results suggest GlyT-1 inhibition is not a broadly effective or optimal therapeutic strategy to enhance NMDA glutamate receptor function in schizophrenia."

The trials were carried out over 201 sites, with each trial including about 600 patients with persistent, predominant negative symptoms of schizophrenia. Patients treated with antipsychotics were administered placebo or bitopertin (5, 10, or 20 mg) for 24 weeks. The doses were chosen to test the minimal effective dose (5 mg) and the dose with a predicted maximal effect (20 mg).

All participants showed some improvement in the negative symptom factor score, but there were no differences between placebo or bitopertin treatment at 24 weeks. No differences were observed in other symptom domains of schizophrenia either. All three doses of bitopertin were well-tolerated and generally safe over the course of the study.

According to Bugarski-Kirola, tackling complex clinical, regulatory and commercial development processes, reliability and quality control was a daunting task when dealing with over 200 study sites across different cultures. "We demonstrated that quality can be accomplished across the sites, but consider a different approach to the design," she said, explaining that rather than treating negative symptom patients as one homogenous target, priority should be given to exploring the usefulness of novel mechanisms in separate negative symptom domains to better define the target population and maximize the chance of success before launching large phase III trials.

Explore further: Disproving hypothesis clears path for research for new treatment options for schizophrenia

More information: Dragana Bugarski-Kirola et al. Bitopertin in Negative Symptoms of Schizophrenia?Results From the Phase III FlashLyte and DayLyte Studies, Biological Psychiatry (2017). DOI: 10.1016/j.biopsych.2016.11.014

Related Stories

Disproving hypothesis clears path for research for new treatment options for schizophrenia

March 10, 2016
Researchers reported results from the first repeated-dose study of a dopamine-1 receptor (D1R) agonist for treating the cognitive and negative symptoms of schizophrenia today in the Journal of Psychopharmacology.

Clinical trial: First treatment for 'emotional flatness' associated with schizophrenia

August 30, 2015
Results of a clinical trial seem to show the first effective treatment for the negative symptoms - withdrawal, lack of emotion, and apathy - associated with schizophrenia. This work is presented at the European College of ...

Study suggests valproate may be effective in patients with variant of COMT gene

September 14, 2016
A drug prescribed to many patients with schizophrenia or bipolar disorder may decrease negative symptoms for people with a certain variant of the COMT gene, suggests a new study from researchers at Columbia University Medical ...

A comparison between quetiapine and aripiprazole for treatment of schizophrenia

July 13, 2016
Schizophrenia is a common cause of incapacity and is ranked as the third-most-disabling illness subsequent to dementia and quadriplegia. Nearly, 75% of persons with schizophrenia have continuing problems with recurrent psychotic ...

New schizophrenia treatments may be effective for subgroup of patients

December 8, 2015
Mounting evidence indicates that disturbances in the brain's glutamate pathway contribute to symptoms of schizophrenia. Thus, the glutamate pathway has become the target of a number of new drug therapies. Findings published ...

New medication significantly decreases involuntary movement

April 7, 2017
Antipsychotic treatment can cause involuntary movements such as lip smacking, tongue protrusions and excessive eye blinking. These movements typically occur after more than 3 months of treatment and are called tardive dyskinesia.

Recommended for you

Researchers identify brain mechanism linking PTSD and opioid addiction

April 23, 2018
Researchers at Western University have shown that the recall of traumatic memories enhances the rewarding effects of morphine, shedding light on the neurobiological link between post-traumatic stress disorder (PTSD) and opioid ...

Scientific guidelines for using cannabis to treat stress, anxiety and depression

April 19, 2018
In a first-of-a-kind study, Washington State University scientists examined how peoples' self-reported levels of stress, anxiety and depression were affected by smoking different strains and quantities of cannabis at home.

Neuroscientists use magnetic stimulation to amplify PTSD therapy

April 19, 2018
Researchers from The University of Texas at Dallas have found that a standard therapy for post-traumatic stress disorder (PTSD) is more effective when paired with transcranial magnetic stimulation of the brain.

Research reveals stronger people have healthier brains

April 19, 2018
A study of nearly half a million people has revealed that muscular strength, measured by handgrip, is an indication of how healthy our brains are.

Study suggests we can recognize speakers only from how faces move when talking

April 18, 2018
Results of a new study by cognitive psychologist and speech scientist Alexandra Jesse and her linguistics undergraduate student Michael Bartoli at the University of Massachusetts Amherst should help to settle a long-standing ...

Scientists disconfirm belief that humans' physiological reaction to emotions are uniform

April 18, 2018
How do you feel when you're angry? Tense? Jittery? Exhausted? Is it the same every time? Is it identical to how your best friend, co-worker, or barista feel when they experience anger? In all likelihood the answer is no, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.